共 50 条
- [21] A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitisJOURNAL OF CROHNS & COLITIS, 2020, 14 : S021 - S022Ben-Horin, S.Leszczyszyn, J.Dudkowiak, R.Lahat, A.Gawdis-Wojnarska, B.Pukitis, A.Horynski, M.Farkas, K.Kierkus, J.Kowalski, M.Ye, B. D.Reinisch, W.Lee, S. J.Kim, S. H.Kim, M. R.Kim, Y. A.Kim, H. N.Schreiber, S.
- [22] Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort StudyJOURNAL OF CROHNS & COLITIS, 2022, 16 (09): : 1436 - 1446Smith, Philip J.Critchley, LisaStorey, DanielGregg, BelleStenson, JuneKneebone, AndrewRimmer, TracyBurke, StevenaHussain, ShamasYi Teoh, WanVazeille, StephanSerna, SolangeSteel, AlanDerbyshire, EdmundCollins, PaulDibb, MartynFlanagan, PaulProbert, ChristopherVerma, Ajay M.Subramanian, Sreedhar
- [23] Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance DataARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3495 - 3498Baraliakos, XenofonKyburz, DiegoAvouac, JeromeBarkham, NickLee, Soohyun
- [24] Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC studyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1727 - I1728Sands, B. E.Hanauer, S. B.Colombel, J. F.Sandborn, W. J.Schreiber, S.Danese, S.Klopocka, M.Kulynych, R.Kierkus, J.Soltysiak, A.Smolinski, P.Gonciarz, M.Sreckovic, S.Valuyskikh, E.Horynski, M.Gasbarrini, A.Lee, S. J.Kim, S.Bae, Y.Lee, S.Lee, S. G.Lee, J. H.Kim, J. M.Lee, J.
- [25] Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitisALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1309 - 1319Hanzel, JurijBukkems, Laura H.Gecse, Krisztina B.D'Haens, Geert R.Mathot, Ron A. A.
- [26] SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDYGASTROENTEROLOGY, 2024, 166 (05) : S810 - S810Sandborn, William J.Sands, Bruce E.Hanauer, Stephen B.Colombel, Jean FredericSchreiber, StefanDanese, SilvioKlopocka, MariaKulynych, RomanKierkus, JaroslawSoltysiak, ArturSmolinski, PatrykGonciarz, MaciejSreckovic, SlobodanValuyskikh, EkaterinaHorynski, MarekGasbarrini, AntonioLee, Sang JoonKim, Sung HyunBae, YunjuLee, SunheeLee, Seul GiLee, Joon HoKim, Jong MinLee, Ji Min
- [27] Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)GASTROENTEROLOGY, 2024, 167 (05) : 919 - 933Hanauer, Stephen B.Sands, Bruce E.Schreiber, StefanDanese, SilvioKlopocka, MariaKierkus, JarosawKulynych, RomanGonciarz, MaciejSotysiak, ArturSmolinski, PatrykSreckovic, SlobodanValuyskikh, EkaterinaLahat, AdiHorynski, MarekGasbarrini, AntonioOsipenko, MarinaBorzan, VladimirKowalski, MaciejSaenko, DariaSardinov, RuslanLee, Sang JoonKim, SunghyunBae, YunjuLee, SunheeLee, SeulgiLee, Joon HoYang, SiyoungLee, JiminLee, JuhyunKim, Jong MinPark, GaheeSandborn, William J.Colombel, Jean-Frederic
- [28] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) Over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13.ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3319 - 3319不详
- [29] Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: 2 years results of the LIBERTY-CD studyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1643 - I1644Colombel, J. F.Hanauer, S. B.Sandborn, W. J.Sands, B. E.Schreiber, S.Danese, S.Kierkus, J.Kulynych, R.Klopocka, M.Lahat, A.Gonciarz, M.Osipenko, M.Borzan, V.Kowalski, M.Saenko, D.Sardinov, R.Lee, S. J.Kim, S.Bae, Y.Lee, S.Lee, S. G.Yang, S.Lee, J.Park, G.
- [30] Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in LatviaJOURNAL OF CROHNS & COLITIS, 2023, 17 : 1008 - 1009Yoo, H. K.Jang, M. Y.Kwon, T. S.